Furthermore, we found that FOXA2 knockdown could markedly improve the sensitivity of chemoresistant CRC cells to OXA treatments, as indicated by the decreased cell viability and the number of EdU‐positive cells (Figure S6C,D, Supporting Information). The gene discussed is FOXA2; the disease is colorectal carcinoma.